Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?

In September 2026, Biohaven Ltd. announced a clinical supply agreement with Regeneron Pharmaceuticals to test BHV-1530 in combination with cemiplimab (Libtayo) in patients with solid tumors, following earlier monotherapy and preclinical data suggesting potential synergy with Anti-PD-1 therapy. This new BHV-1530 collaboration builds on an existing supply agreement for Biohaven’s next-generation TROP2-directed ADC BHV-1510, deepening Regeneron’s involvement across Biohaven’s oncology...